Feature | May 18, 2011 | Mladen I. Vidovich, M.D., FACC, FSCAI

Radial Angiography and Intervention Abstracts From ACC and i2 Summit

There were 15 abstracts presented describing radial access and intervention during the American College of Cardiology (ACC) and i2 Summit meeting in April in New Orleans. The scientific work was submitted from all over the world - Canada, South Korea, Australia, the former Yugoslav republic of Macedonia, the United States, Italy and Japan. The abstracts focused on some of the most burning issues in current radial research.
Hibbert et al. from Ottawa, Canada nicely demonstrated that morbidly obese patients (BMI ? 40) had fewer bleeding and access site complications compared to femoral approach. Similarly, Jacobs et al. from the University of Miami elegantly demonstrated that in the very challenging patients with end-stage liver disease and associated coagulopathy and thrombocytopenia radial was a feasible and safe.

Unprotected left main is the specialty of the South Korean investigators. Youn and colleagues reported that crossover to femoral from radial was more likely to occur due to underlying coronary anatomical considerations, rather than patients’ clinical disease.

The group from Wake Forest University showed that failed radial access increases cardiac catheterization laboratory utilization and that in patients with failed radial access, bleeding rates do not substantially differ from femoral access.

The very nicely named Italian “Paprica” trial investigators demonstrated lower rates of short-term mortality with radial access, primarily due to reduction in major bleeding. A Japanese group from tsunami-affected city of Miyagi described very convincingly the safety and efficacy of a 7.5 French sheathless system for complex PCI with a somewhat difficult-to-reconcile zero percent radial occlusion rate. These findings are important, as they demonstrate that large equipment can safely be used with radial approach, particularly if performed in the overall smaller body habitus Japanese population.

Several abstracts tackled the predictors of procedural difficulty in obtaining radial access (newly described in this abstract - Hispanic origin). Sandeep Nathan, M.D., MS, from the University of Chicago, reported very high rates of radial atherosclerosis in a single center (32 percent). Whether transradial PCI is appropriate for STEMI was confirmed by Rha et al. from Seoul – they observed lower in-hospital and six-month cardiac death with transradial PCI when compared to femoral access. The group from Skopje in the former Yugoslav republic of Macedonia reported a non-randomized series of nearly 1,700 ST-elevated myocardial infarction (STEMI) patients treated with femoral (60 percent) and radial access (40 percent). Likely due to selection bias, the transfemoral group had higher mortality and more patients presented with cardiogenic shock. Nonetheless, procedural times were similar with lower access site complications with radial approach. Similarly, Malaipan from Melbourne, Australia, reported that recommended door-to-balloon (D2B) times are achievable with utilization of radial approach in STEMI.

In summary, it is clear that transradial PCI is a global phenomenon. Great minds think alike and it is very encouraging to observe parallel progress in this field on almost all the continents.


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now